{"nctId":"NCT02472886","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection","startDateStruct":{"date":"2015-06-17","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":153,"armGroups":[{"label":"LDV/SOF","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF Coinfected with HIV-1","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV Retreatment","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study\n* Chronic genotype 1 HCV infection\n* HCV treatment-naive\n* HCV RNA \\> 10,000 IU/mL at screening\n* Absence of cirrhosis\n* Screening laboratory values within defined thresholds\n* Use of two effective contraception methods if female of childbearing potential or sexually active male\n\nKey Exclusion Criteria:\n\n* Pregnant or nursing female or male with pregnant female partner\n* Infection with hepatitis B virus (HBV)\n* Current or prior history of clinical hepatic decompensation\n* Chronic use of systemic immunosuppressive agents\n* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol\n* For HIV-1/HCV co-infected individuals:\n\n  * Opportunistic infection within 6 months prior to screening\n  * Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline\n  * Treatment with an antiretroviral (ARV) regimen other than one of those listed in the study protocol\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"96.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"39.0","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.7","spread":null},{"groupId":"OG001","value":"69.5","spread":null},{"groupId":"OG002","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA Change From Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.97","spread":"0.675"},{"groupId":"OG001","value":"-4.34","spread":"0.626"},{"groupId":"OG002","value":"-4.12","spread":"0.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.50","spread":"0.687"},{"groupId":"OG001","value":"-4.76","spread":"0.522"},{"groupId":"OG002","value":"-4.83","spread":"0.630"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.74","spread":"0.723"},{"groupId":"OG001","value":"-4.89","spread":"0.534"},{"groupId":"OG002","value":"-5.08","spread":"0.642"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.74","spread":"0.723"},{"groupId":"OG001","value":"-4.91","spread":"0.536"},{"groupId":"OG002","value":"-5.11","spread":"0.671"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-5.11","spread":"0.671"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as\n\n* On-treatment virologic failure\n\n  * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ, while on treatment (ie, breakthrough),\n  * confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)\n* Relapse\n\n  * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"For HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":"120.5"},{"groupId":"OG001","value":"159","spread":"114.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":"122.7"},{"groupId":"OG001","value":"202","spread":"178.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":"117.8"},{"groupId":"OG001","value":"172","spread":"114.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":67},"commonTop":["Headache","Abdominal pain upper","Dyspepsia","Asthenia","Irritability"]}}}